A phase i study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors

Investigational New Drugs

Volumn 33, Issue 2, 2015, Pages 332-340

  Sasaki, Yasutsuna ^a,d   Miwa, Keisuke ^a,e   Yamashita, Keishi ^a,f   Sunakawa, Yu ^a,g   Shimada, Ken ^a,h   Ishida, Hiroo ^a,d   Hasegawa, Kosei ^a   Fujiwara, Keiichi ^a   Kodaira, Makoto ^b   Fujiwara, Yasuhiro ^b   Namiki, Masayuki ^c   Matsuda, Minami ^c   Takeuchi, Yutaka ^c   Katsumata, Noriyuki ^b,i  

^a SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c EISAI CO LTD   (Japan)

^d SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e KURUME UNIVERSITY HOSPITAL   (Japan)

^f Division of Rehabilitation Medicine   (Japan)

^g SHOWA UNIVERSITY NORTHERN YOKOHAMA HOSPITAL   (Japan)

^h SHOWA UNIVERSITY KOTO TOYOSU HOSPITAL   (Japan)

ⁱ NIPPON MEDICAL SCHOOL MUSASHI KOSUGI HOSPITAL   (Japan)

Author keywords

Farletuzumab; Folate receptor ; Monoclonal antibody; Pharmacokinetics; Phase I study

Indexed keywords

ANTINEOPLASTIC AGENT; FARLETUZUMAB; FOLATE RECEPTOR 1; MONOCLONAL ANTIBODY;

ADULT; AGED; AREA UNDER THE CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOSYNTHESIS; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; GASTROINTESTINAL NEOPLASMS; HALF LIFE TIME; HUMAN; JAPAN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; OVARIAN NEOPLASMS; PHASE 1 CLINICAL TRIAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLATE RECEPTOR 1; GASTROINTESTINAL NEOPLASMS; HALF-LIFE; HUMANS; JAPAN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; OVARIAN NEOPLASMS;

EID: 84939959461     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0180-8     Document Type: Article

References (20)

1. Wakao F, Nishimoto H, Katanoda K, Tsukuma H, Mikami H, eds (2013) Cancer statistics in Japan 2013. Foundation for Promotion of Cancer Research, Tokyo. http://ganjoho.jp/pro/statistics/en/backnumber/2013-en.html. Accessed 7 Aug 2014
2. Vital statistics in Japan, tabulated by Center for Cancer Control and Information Services, National Cancer Center, Japan. http://ganjoho.jp/pro/statistics/en/table-download.html. Accessed 7 Aug 2014
3. Kelemen LE (2006) The role of folate receptor α in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer 119:243-250
4. Campbell IG, Jones TA, Foulkes WD, Trowsdale J (1991) Folate-binding protein is a marker for ovarian cancer. Cancer Res 51:5329-5338
5. Ebel W, Routhier EL, Foley B et al (2007) Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun 7:6-13
6. Garin-Chesa P, Campbell I, Saigo PE, Lewis JL Jr, Old LJ, Rettig WJ (1993) Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol 142:557-567
7. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M (1997) Overexpression of folate binding protein in ovarian cancers. Int J Cancer 74:193-198
8. O'Shannessy DJ, Somers EB, Smale R, Fu YS (2013) Expression of folate receptor-α (FRA) in gynecologic malignancies and its relationship to the tumor type. Int J Gynecol Pathol 32:258-268
9. Lin J, Spidel JL, Maddage CJ et al (2013) The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity. Cancer Biol Ther 14:1032-1038
10. Konner JA, Bell-McGuinn KM, Sabbatini P et al (2010) Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 16:5288-5295
11. Armstrong DK, White AJ, Weil SC, Phillips M, Coleman RL (2013) Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol 129:452-458
12. [No authors listed] (2004) Japanese translation of common terminology criteria for adverse events (CTCAE), and instructions and guidelines. Int J Clin Oncol 9 Suppl III:1-82
13. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
14. Lobo ED, Hansen RJ, Balthasar JP (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93:2645-2668
15. Vergote IB, Armstrong D, Scambia G et al (2013) Phase 3 double-blind, placebo-controlled study of weekly farletuzumab with carboplatin/taxane in subjects with platinum-sensitive ovarian cancer in first relapse. Int J Gynecol Cancer 8(Suppl 1):11, 118th International meeting of the European Society of Gynecological Oncology (ESGO), 2013, October 19-22; Liverpool, UK
16. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208
17. Kang JH, Lee SI, Lim Do H et al (2012) Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30:1513-1518
18. Hironaka S, Ueda S, Yasui H et al (2013) Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 31:4438-4444
19. Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687-697
20. Fuchs CS, Tomasek J, Yong CJ et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31-39